| Mr Hermilo Gonzalez Jr, MD | |
|
497 W Lott St, Buffalo, WY 82834-1609 | |
| (307) 684-2228 | |
| (307) 684-2177 |
| Full Name | Mr Hermilo Gonzalez Jr |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 39 Years |
| Location | 497 W Lott St, Buffalo, Wyoming |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023096153 | NPI | - | NPPES |
| 306232 | Other | WY | BLUE CROSS |
| 306039 | Other | WY | BLUE CROSS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 4374A (Wyoming) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Johnson Co Healthcare Ctr Home Health Agency | Buffalo, WY | Home health agency |
| Johnson County Healthcare Center | Buffalo, WY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Family Medical Center | 1557344371 | 17 |
News Archive
Relypsa, Inc., today announced the initiation of patient enrollment in a Phase 2, open-label titration clinical study of the company's lead drug candidate, RLY5016, in heart failure patients with chronic kidney disease. RLY5016 is a novel non-absorbed oral potassium binder intended to prevent and treat hyperkalemia, a serious condition characterized by elevated serum potassium levels.
Scientists have shown in multiple contexts that DNA damage over our lifetimes is a key mechanism behind the development of cancer and other age-related diseases. Not everyone gets these diseases, because the body has multiple mechanisms for repairing the damage caused to DNA by aging, the environment and other human behaviors - but the mechanisms behind certain kinds of DNA repair have not been well-understood.
Infertile men are at nearly three times greater risk for developing clinically significant prostate cancer than the average man according to a new study published in the journal, Cancer.
Dr Guishui Zhang and Associate Professor Levon Khachigian, from the Centre for Vascular Research, and Dr Nick Di Girolamo of the School of Medical Sciences were part of a team which suppressed a protein in the cells lining blood vessels.
DelMar Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today presented updated clinical data from its Phase I/II study of lead product candidate VAL-083 (dianhydrogalactitol), in patients with refractory glioblastoma multiforme (GBM), at GBM2015: 2nd International Symposium on Clinical and Basic Investigation in Glioblastoma in Toledo, Spain.
› Verified 8 days ago
| Entity Name | Family Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285612317 PECOS PAC ID: 1557344371 Enrollment ID: O20040611000248 |
News Archive
Relypsa, Inc., today announced the initiation of patient enrollment in a Phase 2, open-label titration clinical study of the company's lead drug candidate, RLY5016, in heart failure patients with chronic kidney disease. RLY5016 is a novel non-absorbed oral potassium binder intended to prevent and treat hyperkalemia, a serious condition characterized by elevated serum potassium levels.
Scientists have shown in multiple contexts that DNA damage over our lifetimes is a key mechanism behind the development of cancer and other age-related diseases. Not everyone gets these diseases, because the body has multiple mechanisms for repairing the damage caused to DNA by aging, the environment and other human behaviors - but the mechanisms behind certain kinds of DNA repair have not been well-understood.
Infertile men are at nearly three times greater risk for developing clinically significant prostate cancer than the average man according to a new study published in the journal, Cancer.
Dr Guishui Zhang and Associate Professor Levon Khachigian, from the Centre for Vascular Research, and Dr Nick Di Girolamo of the School of Medical Sciences were part of a team which suppressed a protein in the cells lining blood vessels.
DelMar Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today presented updated clinical data from its Phase I/II study of lead product candidate VAL-083 (dianhydrogalactitol), in patients with refractory glioblastoma multiforme (GBM), at GBM2015: 2nd International Symposium on Clinical and Basic Investigation in Glioblastoma in Toledo, Spain.
› Verified 8 days ago
| Entity Name | Johnson County Memorial Hospital |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1003894122 PECOS PAC ID: 5193610947 Enrollment ID: O20070418000297 |
News Archive
Relypsa, Inc., today announced the initiation of patient enrollment in a Phase 2, open-label titration clinical study of the company's lead drug candidate, RLY5016, in heart failure patients with chronic kidney disease. RLY5016 is a novel non-absorbed oral potassium binder intended to prevent and treat hyperkalemia, a serious condition characterized by elevated serum potassium levels.
Scientists have shown in multiple contexts that DNA damage over our lifetimes is a key mechanism behind the development of cancer and other age-related diseases. Not everyone gets these diseases, because the body has multiple mechanisms for repairing the damage caused to DNA by aging, the environment and other human behaviors - but the mechanisms behind certain kinds of DNA repair have not been well-understood.
Infertile men are at nearly three times greater risk for developing clinically significant prostate cancer than the average man according to a new study published in the journal, Cancer.
Dr Guishui Zhang and Associate Professor Levon Khachigian, from the Centre for Vascular Research, and Dr Nick Di Girolamo of the School of Medical Sciences were part of a team which suppressed a protein in the cells lining blood vessels.
DelMar Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today presented updated clinical data from its Phase I/II study of lead product candidate VAL-083 (dianhydrogalactitol), in patients with refractory glioblastoma multiforme (GBM), at GBM2015: 2nd International Symposium on Clinical and Basic Investigation in Glioblastoma in Toledo, Spain.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr Hermilo Gonzalez Jr, MD 497 West Lott, Buffalo, WY 82834-1609 Ph: (307) 684-2228 | Mr Hermilo Gonzalez Jr, MD 497 W Lott St, Buffalo, WY 82834-1609 Ph: (307) 684-2228 |
News Archive
Relypsa, Inc., today announced the initiation of patient enrollment in a Phase 2, open-label titration clinical study of the company's lead drug candidate, RLY5016, in heart failure patients with chronic kidney disease. RLY5016 is a novel non-absorbed oral potassium binder intended to prevent and treat hyperkalemia, a serious condition characterized by elevated serum potassium levels.
Scientists have shown in multiple contexts that DNA damage over our lifetimes is a key mechanism behind the development of cancer and other age-related diseases. Not everyone gets these diseases, because the body has multiple mechanisms for repairing the damage caused to DNA by aging, the environment and other human behaviors - but the mechanisms behind certain kinds of DNA repair have not been well-understood.
Infertile men are at nearly three times greater risk for developing clinically significant prostate cancer than the average man according to a new study published in the journal, Cancer.
Dr Guishui Zhang and Associate Professor Levon Khachigian, from the Centre for Vascular Research, and Dr Nick Di Girolamo of the School of Medical Sciences were part of a team which suppressed a protein in the cells lining blood vessels.
DelMar Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today presented updated clinical data from its Phase I/II study of lead product candidate VAL-083 (dianhydrogalactitol), in patients with refractory glioblastoma multiforme (GBM), at GBM2015: 2nd International Symposium on Clinical and Basic Investigation in Glioblastoma in Toledo, Spain.
› Verified 8 days ago
Mr. Brian Mitchell Darnell, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 497 W Lott, Buffalo, WY 82834 Phone: 307-684-2228 Fax: 307-684-2177 | |
Ms. Grace Marie Gosar, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 497 W Lott St, Buffalo, WY 82834 Phone: 307-684-2228 Fax: 307-684-2177 | |
Mr. Aubrey Dozier Tabb, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 497 W Lott St, Buffalo, WY 82834 Phone: 307-684-2228 Fax: 307-684-2177 | |
Dr. Jennifer Ann Rice, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 497 W Lott St, Buffalo, WY 82834 Phone: 307-684-2228 Fax: 307-684-2177 | |
Mr. Mark Steven Schueler, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 497 West Lott, Buffalo, WY 82834 Phone: 307-684-2228 Fax: 307-684-2177 | |
Mr. Lawrence Edward Kirven, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 497 W Lott St, Buffalo, WY 82834 Phone: 307-684-2228 Fax: 307-684-2177 |